Veracyte Property Plant Equipment Over Time
| VCYT Stock | USD 42.89 0.05 0.12% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Veracyte Performance and Veracyte Correlation. Veracyte |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Veracyte. If investors know Veracyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Veracyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.13) | Revenue Per Share 5.644 | Quarterly Revenue Growth 0.286 | Return On Assets 0.0107 | Return On Equity (0.01) |
The market value of Veracyte is measured differently than its book value, which is the value of Veracyte that is recorded on the company's balance sheet. Investors also form their own opinion of Veracyte's value that differs from its market value or its book value, called intrinsic value, which is Veracyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Veracyte's market value can be influenced by many factors that don't directly affect Veracyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Veracyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Veracyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Veracyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Property Plant Equipment Analysis
Compare Veracyte and related stocks such as Crinetics Pharmaceuticals, Viridian Therapeutics, and Cytokinetics Property Plant Equipment Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRNX | 224 K | 224 K | 224 K | 224 K | 224 K | 224 K | 224 K | 400 K | 4.2 M | 6.5 M | 5.4 M | 4.7 M | 5 M | 5.7 M | 4.2 M |
| VRDN | 625 K | 625 K | 625 K | 625 K | 625 K | 625 K | 625 K | 563 K | 727 K | 523 K | 787 K | 375 K | 1.3 M | 1.5 M | 774.1 K |
| CYTK | 9.7 M | 1.3 M | 997 K | 1.2 M | 1.6 M | 1.8 M | 3.6 M | 3.6 M | 3.2 M | 4.5 M | 13.3 M | 73.3 M | 80.5 M | 92.5 M | 97.1 M |
| GPCR | 277 K | 277 K | 277 K | 277 K | 277 K | 277 K | 277 K | 277 K | 277 K | 277 K | 277 K | 1.8 M | 1.3 M | 1.5 M | 1.2 M |
| KURA | 27 K | 27 K | 27 K | 27 K | 27 K | 71 K | 40 K | 10 K | 278 K | 278 K | 2 M | 2.7 M | 2.5 M | 2.9 M | 3.1 M |
| PTGX | 415 K | 415 K | 415 K | 415 K | 415 K | 609 K | 562 K | 879 K | 861 K | 7.7 M | 1.5 M | 6.7 M | 1.6 M | 1.8 M | 2.5 M |
| MRUS | 388 K | 388 K | 388 K | 388 K | 427 K | 351.5 K | 648 K | 1.2 M | 5.2 M | 8.9 M | 8 M | 7.3 M | 24.8 M | 28.6 M | 30 M |
| REPL | 342 K | 342 K | 342 K | 342 K | 342 K | 342 K | 342 K | 370 K | 12.2 M | 58.2 M | 7.4 M | 55.6 M | 55.6 M | 63.9 M | 67.1 M |
| ENTA | 534 K | 611 K | 1.1 M | 1.8 M | 5.9 M | 8 M | 8 M | 8.4 M | 10.9 M | 8.6 M | 10.7 M | 29.7 M | 29.7 M | 34.2 M | 35.9 M |
| SNDX | 33 K | 33 K | 33 K | 33 K | 33 K | 88 K | 260 K | 267 K | 373 K | 997 K | 192 K | 278 K | 1.1 M | 1.2 M | 1.3 M |
| VTYX | 254 K | 254 K | 254 K | 254 K | 254 K | 254 K | 254 K | 254 K | 254 K | 254 K | 254 K | 254 K | 407 K | 468.1 K | 363.6 K |
| QURE | 1.6 M | 1.6 M | 1.6 M | 3.6 M | 23.8 M | 26 M | 35.7 M | 34.3 M | 29.2 M | 28.8 M | 32.3 M | 43.5 M | 83.3 M | 95.7 M | 100.5 M |
| RCKT | 812 K | 812 K | 812 K | 812 K | 812 K | 812 K | 1.1 M | 563 K | 2 M | 29.3 M | 19.2 M | 72.3 M | 77.6 M | 89.3 M | 93.8 M |
| RYTM | 17 K | 17 K | 17 K | 17 K | 17 K | 17 K | 930 K | 840 K | 1.1 M | 5.7 M | 3.2 M | 2.8 M | 2.2 M | 2.5 M | 2.3 M |
| SLDB | 452 K | 452 K | 452 K | 452 K | 452 K | 452 K | 452 K | 2.4 M | 10.4 M | 16.6 M | 11.7 M | 6.5 M | 9.7 M | 11.1 M | 9.1 M |
| MGTX | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 14.1 M | 22 M | 52.9 M | 44 M | 126.3 M | 109.3 M | 125.7 M | 131.9 M |
| IDYA | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 5.2 M | 9.7 M | 9.5 M | 4.8 M | 6.5 M | 7.5 M | 7.2 M |
| ANAB | 579 K | 579 K | 579 K | 579 K | 579 K | 551 K | 471 K | 665 K | 1.4 M | 3 M | 1.8 M | 2.3 M | 2.1 M | 2.4 M | 1.6 M |
| KROS | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.9 M | 1.6 M | 1.3 M | 2 M | 2.3 M | 1.8 M |
Veracyte and related stocks such as Crinetics Pharmaceuticals, Viridian Therapeutics, and Cytokinetics Property Plant Equipment description
My Equities
My Current Equities and Potential Positions
Additional Tools for Veracyte Stock Analysis
When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.